Hiba Zayyad

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Mical Paul, George L. Daikos, Emanuele Durante‐Mangoni et al. · The Lancet Infectious Diseases · 2018 · 624 citations

Life Sciences, Infectious Diseases, Microbiology +14

Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial

Dafna Yahav, Erica Franceschini, Fidi Koppel et al. · Clinical Infectious Diseases · 2018 · 412 citations · Full text

Pharmacy, Infectious Diseases, Internal Medicine +13

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel

Tal Brosh‐Nissimov, Efrat Orenbuch‐Harroch, Michal Chowers et al. · Clinical Microbiology and Infection · 2021 · 365 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +9

Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel

Paul Kuodi, Yanay Gorelik, Hiba Zayyad et al. · npj Vaccines · 2022 · 147 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial

Yaakov Dickstein, Jonathan Lellouche, Maayan Ben Dalak Amar et al. · Clinical Infectious Diseases · 2018 · 126 citations

Life Sciences, Infectious Diseases, Microbiology +17